Sciences
Life sciences, biotech, and research innovation.
Deloitte's Biopharma AI Value Estimates Come With a Timing Catch
Deloitte estimated top biopharma firms could capture $5-7B in AI value. McKinsey and ISPE material show why timelines and validation still lag.
All Articles
CPC Biotech, Multiply Labs Develop Robot-Ready Cell Therapy Connector
CPC Biotech and Multiply Labs announced a robot-optimized aseptic connector for closed cell therapy manufacturing systems.
Lab automation ROI hinges on integration, not instrument sensitivity claims
Waters’ “5x greater sensitivity” claim and LabCollector’s ELN/LIMS AI Co-Scientist point to the same constraint in lab automation: the handoffs, instrument to m
AeroVironment to co-design three autonomous helicopters for NASA's SkyFall Mars mission
AeroVironment’s MacCready Works won work on three autonomous Mars helicopters for NASA’s SkyFall, putting aerospace-grade autonomy, avionics integration, and re
Telehealth "digital waiting rooms" are turning into premium pharma ad slots
New patient-attention data and agency execution details are pushing pharma media plans toward pre- and post-visit virtual care moments.
Roche pTau217 clearance and Labcorp’s Alzheimer’s test bring diagnostics to primary care
New Alzheimer’s pathology tests and lab automation are shifting the bottleneck from assay availability to workflow activation.
Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031
Genentech will spend $750 million on a Hillsboro device fill-finish plant for prefilled syringes and autoinjectors, targeting commercial operations in 2031 and creating 250 manufacturing jobs.
4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%
Genezen will offer 4basebio’s cell-free hpDNA as starting material for viral vectors, a shift that could change how programs specify plasmids, timelines, and CO
Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt
Bristol Myers ended its deal with Cellares, a reminder that cell therapy supply plans still hinge on process fit, not just factory slots.
Argonne’s AI agents push materials R&D toward days-long cycles
Argonne’s new agentic workflows suggest a procurement shift: buy for dataflow and security, not bigger models.
Cancer diagnostics growth is forcing labs to budget for data, not just instruments
MarketsandMarkets forecasts cancer diagnostics will grow from $29.86B in 2026 to $44.92B by 2031. Frost & Sullivan says the constraint is operational: staffing,
Wall Street is split on Circle: TD Cowen sees 31% upside while Morgan Stanley sees 39% downside
TD Cowen initiated Circle with a buy and an $82 target; Morgan Stanley slashed its target to $38, calling stablecoin utility overstated.
Sony and TSMC's $6.3 billion image-sensor bet signals a new era of chip co-investment
Sony and TSMC plan to spend $6.3B jointly on next-gen image-sensor chips, as AI demand reshapes semiconductor supply chains in 2026.
Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR
Myrias Optics names Neil Anderson, Ph.D. as CRO to commercialize its nanoimprint flat optics platform across AI datacenters, AR, and life sciences.
Biopharma's $300 Billion Patent Cliff Is Driving Its Strongest M&A Cycle Since the Pre-Pandemic Peak
More than $300 billion in branded pharmaceutical revenue faces patent expiration by 2030. Big Pharma cannot replace it through internal R&D alone. The result is the most aggressive acquisition cycle since before the pandemic, and it is reshaping how the entire life sciences supply chain does business.
Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic
Quotient Sciences initiates what it calls the first Phase I trial of an AI-designed oral drug formulation, approved by the UK's MHRA.
Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic
Quotient Sciences has initiated a Phase I study of an AI-designed oral formulation, cleared by the MHRA, marking a concrete shift from AI experimentation to clin
Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026
At Paris Packaging Week 2026, Tekniplex didn’t just exhibit—it staged an experience that reflected the evolving intersection of materials science and brand storytelling. The company’s modern booth, complete with a living wall and immersive digital displays, signaled a broader shift in how packaging innovators are choosing to engage a sustainability-conscious audience. Beneath the…
Oscar Martin Interview – AMI Single Serve Tampa – 2026
The single-serve coffee industry is at a pivotal moment, where convenience and sustainability are no longer competing priorities but parallel expectations shaping innovation. At gatherings like the AMI Single Serve Coffee Conference in Tampa, the conversation has clearly shifted from abstract goals to tangible, commercially viable solutions—especially in the realm of compostable and recyclable…
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…
What the Future Looks Like if We Get It Right
As the Patient Monitoring series concludes, the conversation shifts from today’s challenges to tomorrow’s possibilities. This final episode of the five-part Health and Life Sciences at the Edge series looks ahead to what healthcare could become if patient monitoring gets it right. Intel’s Kaeli Tully is joined by Sudha Yellapantula, Senior Researcher at Medical…
Why Is the Mission of Benchmark So Important
As pharmaceutical innovation accelerates, the margin for error narrows, making quality assurance not just a regulatory necessity but a public good. Benchmark’s mission sits at the intersection of progress and protection—helping manufacturers stay aligned with FDA standards so life-saving therapies reach patients faster and safer. By keeping cleanrooms compliant and companies out of trouble, Benchmark…
What Is It Like for You to Be Part of the Benchmark Products Teams Now
Being part of the Benchmark Products team today means working at the intersection of precision manufacturing and deeply human collaboration, especially in the high-stakes world of cleanroom and sterility assurance solutions. As the organization grows, employees describe a culture that still feels familial—one where clear communication, personal accountability, and genuine care for customers drive…
Why We Show Up for Care
Episode 4 of The Future of Patient Monitoring takes a step back from infrastructure and innovation to explore something deeper: the people behind the technology—and what they’ve learned through years of building smarter systems. Part of the Health and Life Sciences at the Edge podcast series, this conversation is led by Intel’s Kaeli Tully,…
What Exactly Is a 5-Log Reduction, and Why Does It Matter for Cleanroom Teams
In cleanroom environments, contamination control isn’t about vague cleanliness—it’s about measurable reductions, and a 5-log reduction means cutting microbial presence by 99.999%, turning 100,000 bacteria into just one. For cleanroom teams, this level of performance before disinfectants are even applied is critical, because it dramatically lowers bioburden risk and strengthens the effectiveness of every…
Why Does Benchmark’s Work Need More Visibility
In an industry defined by rapid scientific breakthroughs, Benchmark Products plays a quietly pivotal role—translating innovation into tangible tools that life sciences manufacturers can actually use. By staying aligned with the evolving needs of patients and producers alike, Benchmark has built a reputation for agility, rapidly manufacturing solutions that improve efficiency and enable new…
My Biggest Takeaway from NC State’s Bioprocessing Course
Hands-on immersion has become a defining advantage in modern biomanufacturing, and programs like NC State’s BTEC exemplify why experiential learning matters as much as technical knowledge. By stepping through a full upstream and downstream bioprocess in a simulated environment, the Benchmark team gained firsthand insight into the real-world pressures, decisions, and constraints their customers…
Lamar IoT’s Cutting-Edge Tracking Tech Prevents Drugs & High-End Food Products from Perishing
Real-time condition monitoring prevents costly losses of temperature-sensitive pharmaceuticals and perishables across complex global supply chains
New to MarketScale?
MarketScale is the B2B media platform Sciences companies use to publish their own experts. The coverage above is produced on it. Fifteen minutes with our team and you'll know if it fits.